Genentech/Roche cancels CREED-1 and d CREED 2 Phase III trials of crenezumab for Alzheimer's Disease
Genentech, a member of the Roche Group, announced the decision to discontinue CREAD 1 and CREAD 2 (BN29552 and BN29553) Phase III studies of the investigational anti-beta-amyloid molecule crenezumab in people with early (prodromal to mild) sporadic Alzheimer�s disease (AD).
The decision was based on the results of a pre-planned interim analysis assessing the safety and efficacy of crenezumab conducted by the Independent Data Monitoring Committee, which indicated that crenezumab was unlike . No safety signals for crenezumab were observed in this analysis, and the overall safety profile was similar to that seen in previous trials. Data from the CREAD 1 and 2 studies will be shared with the scientific community at an upcoming medical congress. Findings from the trials will inform future research programs, approaches and clinical trial designs.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins